-

Doctors Turning to Contrast Enhanced Ultrasound for Superior Results Without Realizing Reimbursement Is Also Favorable

CHICAGO--(BUSINESS WIRE)--Doctors are finding that contrast enhanced ultrasound (CEUS) is so effective in imaging kidney masses in patients with polycystic kidney disease that “they go right to CEUS and no longer bother with CT,” Dr. Richard Barr said Friday at the annual Advances in Contrast Ultrasound conference in Chicago.

Dr. Barr, a radiologist in Youngstown, Ohio and an officer of the International Contrast Ultrasound Society (ICUS), said that his colleagues, including nephrologists, often favor CEUS because it quickly produces accurate and reliable results without the high cost, risk of kidney damage and exposure to radiation associated with contrast CT or MR.

And CEUS is not just good for patients, according to Barr.

“Many doctors don’t realize that they get paid more for using CEUS when compared to CT or MR with contrast, and reimbursement is available no matter what organ you are examining and no matter which ultrasound contrast agent you use,” Barr said.

CEUS, along with grayscale ultrasound, have “a critical role to play” in detecting solid renal masses, according to a report presented by ICUS Board Member Christine Merrill, a sonographer in the Department of Radiology at the University of Calgary.

She reviewed the recent case of a 70-year old patient with adult polycystic kidney disease initially examined with CT, which identified a single suspect mass in the right kidney. The patient was then referred for CEUS, which found 5 solid masses across both kidneys.

Ultrasound contrast agents are biocompatible suspensions of echogenic microbubbles that are injected intravenously during an ultrasound exam to help identify tumors and other abnormalities of the kidneys, liver, bowel, heart and other organ systems.

Ultrasound contrast agents are sold by Bracco, GE Healthcare and Lantheus.

ABOUT ICUS:

The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources.

To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

International Contrast Ultrasound Society


Release Summary
Doctors are finding that CEUS is so effective in imaging kidney masses in patients that they go straight to CEUS and no longer bother with CT.
Release Versions

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

More News From International Contrast Ultrasound Society

CMS Doubles Payment for Contrast-Enhanced Ultrasound Scans

CHICAGO--(BUSINESS WIRE)--Payment for certain contrast-enhanced ultrasound (CEUS) imaging procedures will double under a newly assigned billing code, according to an announcement by the International Contrast Ultrasound Society (ICUS) which advocated for the reimbursement upgrade. The change, published in the Federal Register today and effective January 1, 2026, will increase non-cardiac CEUS reimbursement from $170.02 to $358.35. It also reassigns non-cardiac CEUS to the same billing code used...

Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors

CHICAGO--(BUSINESS WIRE)--Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study assessed 193 kidney lesions in 188 patients at two medical centers over approximately six years, ac...

New Studies Show Microbubble Ultrasound Contrast Agents Improve Liver Tumor Response to Radiotherapy and Survival

CHICAGO--(BUSINESS WIRE)--Two new clinical trials show that microbubble ultrasound contrast agents safely and effectively improve liver tumor responses to radiotherapy and patient survival, according to results announced today by Dr. John Eisenbrey, professor of radiology at Thomas Jefferson University, at the 39th annual International Bubble Conference in Chicago. One study found that patients with aggressive intrahepatic cholangiocarcinoma (ICC) and liver metastasis showed a greater than 50%...
Back to Newsroom